Pricing

Arvinas Inc (ARVN)

followers ยท
Sector: HEALTH CARE
Industry: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
CEO: John G. Houston
Employees: 420
Web site: arvinas.com
395 WINCHESTER AVE, 5 SCIENCE PARK, NEW HAVEN, CT, 06511
203-535-1456
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available